<p>再生元製藥（NASDAQ:REGN - 獲取免費報告）在摩根士丹利發佈的一份研究報告中，將其目標價格從 767.00 美元上調至 768.00 美元。該券商目前對這家生物製藥公司的股票給予 “持平” 評級。摩根士丹利的目標價格表明，從公司當前價格來看，潛在上漲幅度為 4.12%。</p>
<ul>
<li>5 個醫療保健股票值得關注，因為行業輪動已全面展開</li>
</ul>
<p>其他一些研究公司也最近對 REGN 發表了評論。Truist Financial 在 11 月 24 日的報告中開始覆蓋再生元製藥。他們對該公司的評級為 “買入”，目標價格為 798.00 美元。Weiss Ratings 在週一的報告中重新發布了對再生元製藥的 “持有（c）” 評級。華爾街 Zen 在 11 月 17 日的報告中將再生元製藥的評級從 “持有” 上調至 “買入”。Guggenheim 在 10 月 29 日的研究報告中將再生元製藥的目標價格從 815.00 美元上調至 865.00 美元，並給予該公司 “買入” 評級。最後，Cantor Fitzgerald 在 10 月 29 日的報告中將再生元製藥的目標價格從 678.00 美元上調至 740.00 美元，並給予該股票 “超配” 評級。三位投資分析師給予該股票 “強烈買入” 評級，十五位分析師給予 “買入” 評級，九位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，再生元製藥的共識評級為 “適度買入”，共識目標價格為 779.45 美元。</p>
<p><strong>查看我們關於 REGN 的最新研究報告</strong></p>
<h2>再生元製藥股價下跌 1.2%</h2>
<ul>
<li>大跌者：3 只接近一年低點的股票，可能在 2025 年大幅上漲</li>
</ul>
<p>再生元製藥的股票在週五的午盤交易中下跌了 9.22 美元，跌至 737.58 美元。該股票的交易量為 233,919 股，而其平均交易量為 1,096,572 股。再生元製藥的 52 周低點為 476.49 美元，52 周高點為 790.98 美元。該公司的速動比率為 3.33，流動比率為 4.06，債務股本比率為 0.09。該股票的市值為 775.2 億美元，市盈率為 17.66，市盈增長比率為 2.08，貝塔值為 0.37。該公司的 50 日簡單移動平均線為 661.61 美元，200 日簡單移動平均線為 591.76 美元。</p>
<p>再生元製藥（NASDAQ:REGN - 獲取免費報告）最近一次發佈財報是在 10 月 28 日，生物製藥公司報告該季度每股收益為 11.83 美元，超出市場共識預期的 9.73 美元，超出幅度為 2.10 美元。該公司該季度的收入為 37.5 億美元，而分析師預期為 35.7 億美元。再生元製藥的股本回報率為 13.76%，淨利潤率為 32.13%。該公司該季度的收入同比增長 0.9%。在去年同期，該公司每股收益為 12.46 美元。股票研究分析師預計再生元製藥在當前財政年度將發佈 35.92 美元的每股收益。</p>
<h2>再生元製藥的內部交易</h2>
<ul>
<li>2025 年值得購買的最佳生物技術股票</li>
</ul>
<p>在相關消息中，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股公司的股票。該股票的平均售價為 654.27 美元，總交易額為 4,252,755.00 美元。交易完成後，該董事直接持有公司 2,352 股股票，價值 1,538,843.04 美元。此次交易使其持股減少了 73.43%。該交易已在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，副總裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。該股票的平均售價為 651.43 美元，總價值為 280,766.33 美元。交易完成後，該副總裁持有公司 4,233 股股票，價值 2,757,503.19 美元。此次交易使其持股減少了 9.24%。該銷售的 SEC 備案提供了更多信息。公司內部人士持有公司 7.02% 的股票。</p>
<h2>對再生元製藥的對沖基金看法</h2>
<p>幾家機構投資者和對沖基金最近對 REGN 的持倉進行了調整。Allworth Financial LP 在第三季度將其在再生元製藥的持股增加了 50.5%。Allworth Financial LP 目前持有 1,496 股生物製藥公司的股票，價值 841,000 美元，此前在上個季度購買了 502 股。IFP Advisors Inc 在第三季度將其在再生元製藥的持股增加了 14.2%。IFP Advisors Inc 目前持有 1,405 股生物製藥公司的股票，價值 790,000 美元，此前在上個季度增加了 175 股。瑞士人壽資產管理有限公司在第三季度將其在再生元製藥的持股增加了 112.0%。瑞士人壽資產管理有限公司目前持有 23,658 股生物製藥公司的股票，價值 13,302,000 美元，此前在此期間增加了 12,500 股。Cambria Investment Management L.P.在第三季度將其在再生元製藥的持股增加了 21.8%。Cambria Investment Management L.P.目前持有 3,090 股生物製藥公司的股票，價值 1,737,000 美元，此前在上個季度增加了 554 股。最後，Pointe Capital Management LLC 在第三季度將其在再生元製藥的持股增加了 37.0%。Pointe Capital Management LLC 目前持有 719 股生物製藥公司的股票，價值 404,000 美元，此前在上個季度增加了 194 股。機構投資者持有公司 83.31% 的股票。</p>
<h2>再生元製藥公司簡介</h2>
<p>（獲取免費報告）</p>
<p>再生元製藥公司發現、發明、開發、生產和商業化用於治療全球各種疾病的藥物。公司的產品包括用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的 EYLEA 注射劑；近視性脈絡膜新生血管；糖尿病視網膜病變；新生血管性青光眼；以及早產兒視網膜病變。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比再生元製藥更好的股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>博通在財報後下滑，儘管 AI 需求激增</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>高通被稱為 AI 失敗者——那它為何還在上漲？</li>
<li>交易暫停的解釋</li>
<li>2 只小型生物科技公司可能會回報耐心的投資者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在再生元製藥嗎？</h2>
<p>在你考慮再生元製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而再生元製藥並不在名單上。</p>
<p>儘管再生元製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

再生元制藥

<p>摩根士丹利將再生元製藥的目標股價從 767.00 美元上調至 768.00 美元，維持 “持平” 評級。其他分析師的評級各不相同，有的給予 “買入” 評級，有的則為 “持有”。該股票目前交易價格為 737.58 美元，市值為 775.2 億美元。近期注意到內部交易和對沖基金活動，企業內部人士持有該股票的 7.02%</p>

<p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price raised by research analysts at Morgan Stanley from $767.00 to $768.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an &#34;equal weight&#34; rating on the biopharmaceutical company's stock. Morgan Stanley's target price points to a potential upside of 4.12% from the company's current price.</p>
<div class="lb-trans"><p>再生元製藥（NASDAQ:REGN - 獲取免費報告）在摩根士丹利發佈的一份研究報告中，將其目標價格從 767.00 美元上調至 768.00 美元。該券商目前對這家生物製藥公司的股票給予 “持平” 評級。摩根士丹利的目標價格表明，從公司當前價格來看，潛在上漲幅度為 4.12%。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 個醫療保健股票值得關注，因為行業輪動已全面展開</li>
</ul>
</div><p>A number of other research firms have also recently commented on REGN. Truist Financial initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a &#34;buy&#34; rating and a $798.00 price target for the company. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Regeneron Pharmaceuticals in a report on Monday. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, November 17th. Guggenheim increased their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. Finally, Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $779.45.</p>
<div class="lb-trans"><p>其他一些研究公司也最近對 REGN 發表了評論。Truist Financial 在 11 月 24 日的報告中開始覆蓋再生元製藥。他們對該公司的評級為 “買入”，目標價格為 798.00 美元。Weiss Ratings 在週一的報告中重新發布了對再生元製藥的 “持有（c）” 評級。華爾街 Zen 在 11 月 17 日的報告中將再生元製藥的評級從 “持有” 上調至 “買入”。Guggenheim 在 10 月 29 日的研究報告中將再生元製藥的目標價格從 815.00 美元上調至 865.00 美元，並給予該公司 “買入” 評級。最後，Cantor Fitzgerald 在 10 月 29 日的報告中將再生元製藥的目標價格從 678.00 美元上調至 740.00 美元，並給予該股票 “超配” 評級。三位投資分析師給予該股票 “強烈買入” 評級，十五位分析師給予 “買入” 評級，九位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，再生元製藥的共識評級為 “適度買入”，共識目標價格為 779.45 美元。</p>
</div><p><strong>View Our Latest Research Report on REGN</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 REGN 的最新研究報告</strong></p>
</div><h2>Regeneron Pharmaceuticals Trading Down 1.2%</h2>
<div class="lb-trans"><h2>再生元製藥股價下跌 1.2%</h2>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大跌者：3 只接近一年低點的股票，可能在 2025 年大幅上漲</li>
</ul>
</div><p>Regeneron Pharmaceuticals stock traded down $9.22 during midday trading on Friday, hitting $737.58. 233,919 shares of the stock were exchanged, compared to its average volume of 1,096,572. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $790.98. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $77.52 billion, a PE ratio of 17.66, a P/E/G ratio of 2.08 and a beta of 0.37. The company has a fifty day simple moving average of $661.61 and a two-hundred day simple moving average of $591.76.</p>
<div class="lb-trans"><p>再生元製藥的股票在週五的午盤交易中下跌了 9.22 美元，跌至 737.58 美元。該股票的交易量為 233,919 股，而其平均交易量為 1,096,572 股。再生元製藥的 52 周低點為 476.49 美元，52 周高點為 790.98 美元。該公司的速動比率為 3.33，流動比率為 4.06，債務股本比率為 0.09。該股票的市值為 775.2 億美元，市盈率為 17.66，市盈增長比率為 2.08，貝塔值為 0.37。該公司的 50 日簡單移動平均線為 661.61 美元，200 日簡單移動平均線為 591.76 美元。</p>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company's revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $12.46 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>再生元製藥（NASDAQ:REGN - 獲取免費報告）最近一次發佈財報是在 10 月 28 日，生物製藥公司報告該季度每股收益為 11.83 美元，超出市場共識預期的 9.73 美元，超出幅度為 2.10 美元。該公司該季度的收入為 37.5 億美元，而分析師預期為 35.7 億美元。再生元製藥的股本回報率為 13.76%，淨利潤率為 32.13%。該公司該季度的收入同比增長 0.9%。在去年同期，該公司每股收益為 12.46 美元。股票研究分析師預計再生元製藥在當前財政年度將發佈 35.92 美元的每股收益。</p>
</div><h2>Insider Transactions at Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>再生元製藥的內部交易</h2>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年值得購買的最佳生物技術股票</li>
</ul>
</div><p>In related news, Director Christine A. Poon sold 6,500 shares of the business's stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company's stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股公司的股票。該股票的平均售價為 654.27 美元，總交易額為 4,252,755.00 美元。交易完成後，該董事直接持有公司 2,352 股股票，價值 1,538,843.04 美元。此次交易使其持股減少了 73.43%。該交易已在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，副總裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。該股票的平均售價為 651.43 美元，總價值為 280,766.33 美元。交易完成後，該副總裁持有公司 4,233 股股票，價值 2,757,503.19 美元。此次交易使其持股減少了 9.24%。該銷售的 SEC 備案提供了更多信息。公司內部人士持有公司 7.02% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>對再生元製藥的對沖基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in REGN. Allworth Financial LP lifted its stake in Regeneron Pharmaceuticals by 50.5% in the third quarter. Allworth Financial LP now owns 1,496 shares of the biopharmaceutical company's stock worth $841,000 after purchasing an additional 502 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Regeneron Pharmaceuticals by 14.2% in the 3rd quarter. IFP Advisors Inc now owns 1,405 shares of the biopharmaceutical company's stock valued at $790,000 after acquiring an additional 175 shares during the last quarter. Swiss Life Asset Management Ltd boosted its holdings in Regeneron Pharmaceuticals by 112.0% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 23,658 shares of the biopharmaceutical company's stock valued at $13,302,000 after acquiring an additional 12,500 shares during the period. Cambria Investment Management L.P. grew its position in Regeneron Pharmaceuticals by 21.8% during the 3rd quarter. Cambria Investment Management L.P. now owns 3,090 shares of the biopharmaceutical company's stock worth $1,737,000 after acquiring an additional 554 shares during the last quarter. Finally, Pointe Capital Management LLC grew its position in Regeneron Pharmaceuticals by 37.0% during the 3rd quarter. Pointe Capital Management LLC now owns 719 shares of the biopharmaceutical company's stock worth $404,000 after acquiring an additional 194 shares during the last quarter. Institutional investors own 83.31% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近對 REGN 的持倉進行了調整。Allworth Financial LP 在第三季度將其在再生元製藥的持股增加了 50.5%。Allworth Financial LP 目前持有 1,496 股生物製藥公司的股票，價值 841,000 美元，此前在上個季度購買了 502 股。IFP Advisors Inc 在第三季度將其在再生元製藥的持股增加了 14.2%。IFP Advisors Inc 目前持有 1,405 股生物製藥公司的股票，價值 790,000 美元，此前在上個季度增加了 175 股。瑞士人壽資產管理有限公司在第三季度將其在再生元製藥的持股增加了 112.0%。瑞士人壽資產管理有限公司目前持有 23,658 股生物製藥公司的股票，價值 13,302,000 美元，此前在此期間增加了 12,500 股。Cambria Investment Management L.P.在第三季度將其在再生元製藥的持股增加了 21.8%。Cambria Investment Management L.P.目前持有 3,090 股生物製藥公司的股票，價值 1,737,000 美元，此前在上個季度增加了 554 股。最後，Pointe Capital Management LLC 在第三季度將其在再生元製藥的持股增加了 37.0%。Pointe Capital Management LLC 目前持有 719 股生物製藥公司的股票，價值 404,000 美元，此前在上個季度增加了 194 股。機構投資者持有公司 83.31% 的股票。</p>
</div><h2>Regeneron Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>再生元製藥公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p>
<div class="lb-trans"><p>再生元製藥公司發現、發明、開發、生產和商業化用於治療全球各種疾病的藥物。公司的產品包括用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫的 EYLEA 注射劑；近視性脈絡膜新生血管；糖尿病視網膜病變；新生血管性青光眼；以及早產兒視網膜病變。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?</li>
<li>Trading Halts Explained</li>
<li>2 Small-Cap Biotechs That Could Reward Patient Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比再生元製藥更好的股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>博通在財報後下滑，儘管 AI 需求激增</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>高通被稱為 AI 失敗者——那它為何還在上漲？</li>
<li>交易暫停的解釋</li>
<li>2 只小型生物科技公司可能會回報耐心的投資者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在再生元製藥嗎？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮再生元製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而再生元製藥並不在名單上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管再生元製藥目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

摩根士丹利給予再生元製藥（納斯達克股票代碼：REGN）新的目標價為 768.00 美元